Novonesis delivered 9% organic sales growth in H1 and full-year outlook range narrowed to 6-8%

Summary by AI BETAClose X

Novonesis announced H1 2025 results showing 9% organic sales growth, with 8% in Q2. Food & Health segment achieved 10% organic sales growth (9% in Q2), while Planetary Health reached 9% (7% in Q2). Emerging markets grew by 12% (10% in Q2), and developed markets by 8% (6% in Q2). Cost synergies reached 100% run rate. The adjusted EBITDA margin was 37.4% (36.4% in Q2), a 210 bps increase (100 bps in Q2). Adjusted net profit increased by 23% (19% in Q2). NIBD/EBITDA was 2.1x. A EUR 100 million share buyback program was completed. The full-year 2025 outlook was narrowed to 6-8% organic sales growth (previously 5-8%), with 7-9% excluding certain country exits (previously 6-9%). The adjusted EBITDA margin remains at 37-38%. An interim dividend of 2.25 DKK (EUR 0.30) was approved.

Disclaimer*

UK 100

Latest directors dealings